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The lymphatic system is the primary pathway of metastasis for most human cancers. Recent research efforts in studying
lymphangiogenesis have suggested the existence of a relationship between lymphatic vessel density and patient survival. However,
current methodology of lymphangiogenesis quantification is still characterised by high intra- and interobserver variability. For the
amount of lymphatic vessels in a tumour to be a clinically useful parameter, a reliable quantification technique needs to be developed.
With this consensus report, we therefore would like to initiate discussion on the standardisation of the immunohistochemical method
for lymphangiogenesis assessment.
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Metastasis is the leading cause of cancer mortality. Metastatic
cancer cells can escape from their site of origin and spread to
distant organs through invasion of the vascular system and/or the
lymphatic system. Tumour vascularisation is widely accepted as a
bona fide indicator of tumour growth, metastases and patient
survival. In 1996, Peter Vermeulen et al (1996) published a first
international consensus on the methodology and criteria of the
evaluation of angiogenesis quantification in solid tumours and 5
years later, a second consensus report, in which new concepts and
mechanisms of tumour vascularisation were integrated, appeared
(Vermeulen et al, 2002). Both reports were aimed at improving the
standardisation of angiogenesis quantification in order to allow
intratumourous microvessel density to be applied as a prognostic
indicator and, moreover, as a reliable predictor of the risk of
malignant transformation of premalignant lesions and of response
to cancer treatment. Contrary to angiogenesis, the de novo
formation of lymphatic vessels or lymphangiogenesis and its role
in promoting the metastatic spread of tumour cells has only
recently become a focal point of cancer research with an increasing
number of studies showing a relationship between patient survival
and lymphatic density in different tumour types. In order to
confirm the potential prognostic value of lymphangiogenesis in
patients with cancer, a quantification method that is characterised
by a low intra- and interobserver variability needs to be developed.
In this first consensus report, we would like to provide an overview
of current concepts of the lymphatic vasculature and its regulating
factors and propose guidelines for the estimation of the ongoing
lymphangiogenesis in solid human tumour sections.
Structural and molecular characteristics of the lymphatic
vasculature
The vascular and lymphatic systems play complementary roles in
tissue perfusion and subsequent extracellular fluid reabsorption.
Lymphatic vessels comprise a complex open-ended capillary
network that collect lymph from various organs and tissues.
Lymphatic vessels are lined by a single layer of nonfenestrated
endothelium that is attenuated over most of its surface, except in
the perinuclear region which bulges into the lumen (Leak, 1976).
Lymphatic endothelium abut an incomplete or absent basement
membrane and has overlapping junctional complexes. Lymphatics
are attached to the underlying matrix through anchoring filaments
(Leak and Burke, 1968), which keep the vessel patent and therefore
aid lymphatic flow even in areas with elevated hydrostatic pressure
and these filaments may mediate outside-in signalling from the
extracellular matrix akin to integrins. The complex anchoring
filaments–focal adhesions may also control the permeability of
lymphatic endothelium and finely adjust lymph formation to the
physiological conditions of the extracellular matrix.
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lymphatic system. Lymphatic vessels in tissues are absorbing
capillaries with walls consisting solely of endothelium that drain
into collecting vessels. Collecting lymphatic vessels have a thin
circumferential extracellular coat and pericytes that reduce
lymphatic fluid extravasation (Pepper and Skobe, 2003b). The
transition between the absorbing and collecting vessels occurs
gradually and so-called precollectors have been described which
drain into prenodal collecting vessels with an irregular and
tortuous course. The precollectors and collecting lymphatic vessels
also have valves that enable uni-directional lymph flow (Swartz
and Skobe, 2001).
Vascular and lymphatic endothelial cells share many similarities
(Alitalo et al, 2005). Indeed, although initially thought to be
restricted to blood vascular endothelial cells (BVECs), rod-like
electrondense Weibel-Palade bodies containing Factor VIII-related
antigen (von Willebrand factor) have been reported in lymphatic
endothelial cells (LECs) (Di Nucci et al, 1996; Marchetti, 1996;
Sacchi et al, 1999). Furthermore, 98% of genes were expressed at
comparable levels by BVECs and LECs in culture (Petrova et al,
2002; Podgrabinska et al, 2002; Hirakawa et al, 2003) with the
differences in those genes being involved in the regulation of
lymphangiogenesis and lymphatic function (Sleeman et al, 2001)
(vide infra). Nevertheless, akin to vascular endothelium, compara-
tive studies suggest that different lymphatic endothelia have
different phenotypes that are likely to mediate various biological
activities (Garrafa et al, 2006).
Molecular players of tumour lymphangiogenesis
Similar to angiogenesis, the growth of lymphatic vessels is
regulated by a large number of growth factors (Table 1, Figure 1).
Initially, members of the vascular endothelial growth factor
(VEGF) family, VEGF-C and VEGF-D, were thought to be the
only lymphangiogenic factors that stimulate lymphangiogenesis
via activation of VEGFR-3 specifically expressed on normal LECs
(Oh et al, 1997; Achen et al, 1998). The observation that a number
of tumours expressing these two factors at low or undetectable
levels that metastasize via the lymphatic system suggests that
additional signalling systems probably exist (Cao, 2005a).
In xenographic and transgenic mouse tumour models, the
overexpression of VEGF-A in tumours leads to lymphatic
Table 1 Molecular players of lymphangiogenesis
Gene Involvement in lymphangiogenesis Reference
VEGF-C Essential for sprouting the first lymphatic vessel from Prox-1-positive endothelial cells of veins Karkkainen et al (2004)
Overexpression in mouse tumour models promotes the growth of intratumourous lymphatic
vessels and metastasis to regional lymph nodes
Skobe et al (2001), Karpanen et al
(2001)
VEGF-D Overexpression in mouse tumour models induces the formation of lymphatic vessels within the
tumour and leads to spread of the tumour to lymph nodes
Stacker et al (2001)
VEGFR-3 Plays an important role in the development of the lymphatic vasculature Karkkainen et al (2000)
Induces proliferation of cultured LECs Ma ¨kinen et al (2001)
Induces lymphangiogenesis in transgenic mice Veikkola et al (2001)
VEGF-A Overexpression in mouse tumour models induces the growth of peritumourous lymphatic
vessels and leads to lymphatic metastasis
Bjorndahl et al (2005b), Hirakawa
et al (2005)
VEGFR-2 is expressed in LECs Hong et al (2004)
Can induce lymphangiogenesis indirectly by recruiting VEGFR-1 expressing inflammatory cells
including monocytes/macrophages and neutrophils
Cursiefen et al (2004)
FGF-2 Stimulates proliferation, migration and tube formation of cultured LECs Chang et al (2004), Shin et al
(2005)
Induces sprouting of lymphatic vessels in a mouse corneal model can induce lymphangiogenesis
indirectly by recruiting inflammatory cells
Chang et al (2004), Kubo et al
(2002)
PDGF-BB Stimulates cell motility of cultured LECs Cao et al (2004)
Isolated LECs express both PDGFR-alpha and beta
Overexpression in a mouse tumour model stimulates the growth of intratumourous lymphatic
vessels and lymphatic metastasis
Ang-2 Ang-2-knockout mice show disorganised and hypoplastic dermal and intestinal lymphatic
capillaries
Gale et al (2002)
Ang-1 Restores lymphatic defects of Ang-2-knock-out mice Gale et al (2002)
Promotes LYVE-1-positive lymphatic vessel formation in murine cornea Morisada et al (2005)
HGF Stimulates proliferation, migration and tube formation of cultured LECs Kajiya et al (2005)
Induces sprouting and growth of new LYVE-1 expressing lymphatic vessels in mice corneal and
tumour models
Cao et al (2006), Jiang et al (2005)
IGF-1 Stimulates proliferation and migration of cultured LECs Bjorndahl et al (2005a)
IGFR-1 is present in lymphatic endothelium
Induces growth of new LYVE-1 expressing lymphatic vessels in murine cornea
IGF-2 Stimulates proliferation and migration of cultured LECs Bjorndahl et al (2005a)
IGFR-1 and -2 are present in lymphatic endothelium
Induces growth of new LYVE-1 expressing lymphatic vessels in murine cornea
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(Hirakawa et al, 2005; Bjorndahl et al, 2005b). It appears that
VEGF-A indirectly induces lymphangiogenesis by recruiting
VEGFR-1 expressing inflammatory cells including monocytes/
macrophages and neutrophils that produce VEGF-C/-D because
VEGFR-3 antagonists are able to block VEGF-A-induced lym-
phangiogenesis (Cursiefen et al, 2004). However, the direct effect
of VEGF-A on lymphangiogenesis has also been reported since
VEGFR-2 is expressed in LECs (Hong et al, 2004). Similar to
VEGF-A, FGF-2 can indirectly induce lymphangiogenesis via the
VEGF-C/-D/VEGFR-3 pathway by the recruitment of inflammatory
cells, although a recent study also shows that FGF-2 may also
directly stimulate the growth of LECs in vitro and lymphangio-
genesis in vivo (Kubo et al, 2002; Chang et al, 2004; Shin et al,2 0 0 5 ) .
PDGF-BB was only recently described as a direct lymphangiogenic
factor that promotes lymphatic metastasis (Cao et al, 2004). Both
PDGF receptor alpha (PDGFR-a) and beta (PDGFR-b) are
expressed on isolated LECs and all three prototypes of PDGFs,
PDGF-AA, PDGF-BB and PDGF-CC, are able to induce lymph-
angiogenesis (Cao et al, 2004). Members of the angiopoietin (Ang-
1 and -2), hepatocyte growth factor (HGF) and insulin-like growth
factor (IGF-1 and IGF-2) family are newly reported direct
lymphangiogenic factors (Gale et al, 2002; Morisada et al, 2005;
Bjorndahl et al, 2005a; Cao, 2005b).
These known lymphangiogenic factors exhibit overlapping
angiogenic activity on blood vessels. Thus, exposure of these
growth factors to blood vessels and lymphatic vessels leads to
simultaneous stimulation of angiogenesis and lymphangiogenesis
(Cao, 2005b). However, under certain circumstances, both FGF-2
and VEGF-A have been reported to specifically induce only
lymphangiogenesis and not angiogenesis (Chang et al, 2004;
Bjorndahl et al, 2005b). The molecular mechanism underlying the
differential effects of the same factor is currently unknown.
Quantification of tumour lymphangiogenesis: prognostic/
predictive value in oncology
In most cancers, lymph node (LN) metastasis is an important
prognostic factor. However, LN status does not allow a solid
prediction of prognosis for patients presenting with small tumours
without LN involvement. Other reliable markers predictive of LN
metastasis might improve prognostication and might be useful for
therapeutic decision-making in these early cancers. Information
about lymphatic invasion and the number of lymphatic vessels
has been shown promising in this regard. In breast cancer, for
example, the invasion of tumour cells into lymphatic vessels was
shown to be predictive of LN involvement and a prognostic factor
for overall and disease-free survival (Schoppmann et al, 2004; Lee
et al, 2006). Indeed, peritumourous vascular invasion, especially
lymphovascular invasion (LVI), has been included as a novel
adverse prognostic factor in a series of guidelines and recommen-
dations for postoperative adjuvant systemic therapies of early
breast cancer developed by an International Consensus Panel
during the St Gallen Conference, 2005 (Goldhirsch et al, 2005). The
presence of peritumourous vascular invasion defined an inter-
mediate risk for patients with node-negative breast disease, but its
value in patients with node-positive breast disease was considered
uncertain and insufficient at that time. Another clear example is
early gastric cancer, in which the incidence of LN micrometastasis
has been shown to be higher in patients with, than without LVI,
indicating a close link between LVI and the initial stage of LN
metastasis (Arigami et al, 2005). Lymphovascular invasion was
found to be an adverse prognostic indicator in several studies of
gastric cancer (Hyung et al, 2002; Kooby et al, 2003; Dicken et al,
2006). Other examples are node-negative bladder carcinoma
(Lotan et al, 2005) and node-negative oesophageal carcinoma
(Vazquez-Sequeiros et al, 2002) in which LVI was shown to be
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Figure 1 Lymphangiogenic growth factors and their receptors.
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useful information for prognosis and clinical management in those
patients who present with early tumours without LN involvement.
A correlation of lymphatic vessel density (LVD) detected by
immunohistochemistry with an unfavourable prognosis has been
observed in breast cancer, head and neck cancer, melanoma,
cervical cancer, non-small-cell lung cancer, bladder cancer, colo-
rectal cancer and gastric cancer. However, for the amount of
lymphatic vessels in a solid tumour to be a reliable marker of
prognosis, the quantification technique has to be characterised by
a low intra- and interobserver variability. Results obtained at
different institutes should be comparable in order to allow meta-
analyses. Recently, the Programme for the Assessment of Clinical
Cancer Tests Strategy group and a working group of a NCI-EORTC
collaboration have reported guidelines for tumour marker studies
with the objectives of facilitating the evaluation of the appro-
priateness and quality of study design, methods, analyses, and
improving the ability to compare results across studies (McShane
et al, 2005). In Table 2 we listed prognostic studies showing an
association of LVD with the survival of patients with cancer and
indicated how well the REporting Recommendations for tumour
MARKer (REMARK) were followed as a tool for the reader. This
consensus report aims to lower the methodological variability
of lymphangiogenesis quantification in tumour tissue sections,
bearing the REMARK guidelines for prognostic studies in mind.
LYMPHATIC ENDOTHELIAL-SPECIFIC ANTIBODIES
FOR IMMUNOHISTOCHEMISTRY
The selection of the optimal marker of the lymphatic endothelium
is clearly a critical step in the assessment of LVD since false data
arising from low specificity of the staining must be avoided. Major
research efforts during these last years have lead to the discovery
of a large spectrum of candidate lymphatic markers (Figure 2). The
following paragraphs focus on markers for which antibodies are
available and provide a discussion on the specificity of each
marker for LECs.
VEGFR-3
The vascular endothelial growth factor receptor 3 (VEGFR-3/Flt4)
is a tyrosine kinase that is predominantly expressed in LECs in
adult tissues (Kaipainen et al, 1995; Kukk et al, 1996). As VEGFR-3
expression has also been found in fenestrated capillaries of several
organs including the bone marrow, splenic and hepatic sinusoids,
kidney glomeruli and endocrine glands (Partanen et al, 1999) and
in endothelial cells of the proliferating neovasculature in breast
cancer (Valtola et al, 1999), this marker is not reliable for
discriminating between lymphatic and blood vascular endo-
thelium.
Desmoplakin
The glycoprotein desmoplakin locates exclusively to the intracel-
lular junctions between the endothelial cells of lymphatic vessels
(Schmelz and Franke, 1993). Antibodies against desmoplakin have
indicated specificity for lymphatic endothelium in human tongue
(Ebata et al, 2001) but further studies are required to confirm the
distinctive nature of desmoplakin staining in other tissue types.
b-chemokine receptor D6
By using in situ binding assays it was shown that the b-chemokine
receptor D6 is expressed on LECs in the skin (Hub and Rot, 1998).
Monoclonal antibodies raised against the receptor specifically
stained endothelial cells that were also stained with antipodoplanin
antibodies (see below) and showed no immunoreactivity with
endothelial cells lining the blood vessels (Nibbs et al, 2001). D6-
immunoreactive lymphatic vessels were also abundant in mucosa
and submucosa of small and large intestine and appendix, but were
not observed in heart, kidney, liver, skeletal muscle, brain,
cerebellum, pancreas, prostate and thyroid. This demonstrates
the emerging heterogeneity of lymphatic endothelium, and it may
be necessary to use specific markers depending on which tissue is
being investigated.
Prox-1
Another marker of the lymphatic endothelium is the homeo-
domain protein Prox-1, which is required for the regulation of
lymphatic vascular development from pre-existing embryonic
veins (Wigle and Oliver, 1999). Prox-1 expression has also been
found in other cell types, including nonendothelial cells in the lens,
heart, liver, pancreas and nervous system (Stacker et al, 2002).
Antibodies against human Prox-1 to visualise lymphatic vessels in
tumour sections have only been used in a limited number of
studies (Agarwal et al, 2005; Van der Auwera et al, 2005). Although
its nuclear localisation makes Prox-1 not the most ideal marker for
quantifying lymphatic vessels microscopically, it could be a useful
marker for double immunostaining with other markers such as
podoplanin and LYVE-1.
LYVE-1
LYVE-1 is an integral membrane glycoprotein that functions as a
receptor for hyaluronan (GlcNAcb1–4GlcUAb1–3)n, a ubiquitous
extracellular matrix glycosaminoglycan involved in cell migration
and differentiation. The expression of LYVE-1 in endothelial cells
of lymphatic vessels and LN sinuses and its absence from blood
vessel endothelium was first demonstrated by immunohisto-
chemical staining with polyclonal antibodies generated against
recombinant human and murine LYVE-1 Fc fusion protein which
showed characteristic staining of lymphatic vascular structures in
skin, intestine and secondary lymphoid tissue (Banerji et al, 1999;
Prevo et al, 2001). During embryogenesis, LYVE-1 is expressed in
cardinal vein endothelium, just before budding of the primordial
lymph sacs (E12.5 in the mouse), almost simultaneous with the
expression of the lymphogenic transcription factor Prox-1 (Wigle
and Oliver, 1999); expression then persists into adulthood in most
afferent vessels and lymphatic sinuses, but is absent from thoracic
duct. LYVE-1 is also abundant in discontinuous endothelia
including human and mouse liver sinusoids and human spleen
sinusoids but is absent from the ‘normal’ haemovasculature.
Extensive analyses in many different laboratories have confirmed
these findings and demonstrated that LYVE-1 is a reliable marker
for distinguishing lymphatic vessels from blood vessels in a range
of different human cancers (e.g. head and neck squamous cell
carcinoma (Beasley et al, 2002; Maula et al, 2003), cutaneous
melanoma (Dadras et al, 2003; Straume et al, 2003) and
carcinomas of the thyroid (Hall et al, 2003), lung (Koukourakis
et al, 2005), pancreas (Von Marschall et al, 2005), breast (Williams
et al, 2003; Bono et al, 2004), cervix (Van Trappen et al, 2003) and
prostate (Trojan et al, 2004)), as well as normal tissues in both
adult and foetus. Nevertheless, the observation that expression of
LYVE-1 can be downmodulated in some tissues, for example, in
response to inflammation (Johnson L and Jackson DG, unpub-
lished), and is absent in some tumour-associated lymphatics
(Rubbia-Brandt et al, 2004; Stessels et al, 2004; Van der Auwera
et al, 2004) underlines the importance of utilising multiple markers
(e.g. LYVE-1/podoplanin, LYVE-1/Prox-1, etc.) to characterise
lymphatic vessels in comprehensive studies of lymphangiogenesis.
Besides lymphatic and sinusoidal vessel endothelium, LYVE-1 is
also expressed in some macrophage-like cells present in inflamed
tissue and in tumour infiltrates. The special significance of these
findings has been revealed in recent studies of lymphangiogenesis
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British Journal of Cancer (2006) 95(12), 1611–1625 & 2006 Cancer Research UKTable 2 List of studies on the prognostic value of lymphangiogenesis in solid human tumours
Reporting
recommendations for
tumour marker
prognostic studies
Audet
et al
(2005)
Birner
et al
(2001)
Bono
et al
(2004)
Chen
et al
(2004)
Dadras
et al
(2003)
Franchi
et al
(2004)
Gombos
et al
(2005)
Kato
et al
(2005)
Kyzas
et al
(2005)
Massi
et al
(2006)
Maula
et al
(2003)
Miyata
et al
(2006)
Naka-
mura
et al
(2005)
Naka-
mura
et al
(2006)
Omachi
et al
(2006)
Renyi-
Vamos
et al
(2005)
Schopp-
mann
et al
(2004)
Straume
et al
(2003)
No. of
studies in
which
guidelines
were
used
1. State marker examined,
study objectives and
prespecified hypothesis
12
2. Give the patients’
characteristics (source,
inclusion and exclusion
criteria)
8
3. Describe treatments
received and how chosen
10
4. Give the type of biological
material, methods of
preservation and storage
10
5. Specify the assay method;
provide a detailed
protocol (quality control
procedures, reproducibility
assessment, quantitation
methods, scoring and
reporting protocols).
Specify whether and how
assays were performed
blinded to the study end
point
8
6. State the method of case
selection (retrospective or
prospective stratification or
matching). Specify the time
period from which cases
were taken, the end of
follow-up period and the
median follow-up time
1
7. Precisely define all clinical
end points examined
8
8. List all candidate variables
examined or considered
for inclusion in models
NA NA
14
9. Give rationale for sample
size; if the study was
designed to detect a
specified effect size,
give the target power
and effect size
0
10. Specify all statistical
methods (details of any
variable selection
procedures and other
model building
issues, how model
assumptions were verified
and how missing data
were handled
0
11. Clarify how marker
values were handled in
the analyses, if relevant
describe method used for
cut point determination
17
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KTable 2 (Continued)
Reporting
recommendations for
tumour marker
prognostic studies
Audet
et al
(2005)
Birner
et al
(2001)
Bono
et al
(2004)
Chen
et al
(2004)
Dadras
et al
(2003)
Franchi
et al
(2004)
Gombos
et al
(2005)
Kato
et al
(2005)
Kyzas
et al
(2005)
Massi
et al
(2006)
Maula
et al
(2003)
Miyata
et al
(2006)
Naka-
mura
et al
(2005)
Naka-
mura
et al
(2006)
Omachi
et al
(2006)
Renyi-
Vamos
et al
(2005)
Schopp-
mann
et al
(2004)
Straume
et al
(2003)
No. of
studies in
which
guidelines
were
used
12. Describe the flow of
patient s through the
study (the number of
patients included in each
stage of the analysis and
reasons for dropout
15
13. Report distribution of
demographic charac-
teristics (age and sex),
standard prognostic
variables, tumour marker,
number of missing values
14
14. Show the relation of the
marker to standard
prognostic variables
18
15. Present univariate
analyses showing the
relation between the
marker and outcome,
with the estimated effect
(hazard ratio and
survival probability)
9
16. For key multivariate
analyses, report estimated
effect with confidence
intervals for the marker
and all other variables in
the model
NA NA
8
17. Among reported results,
provide estimated effects
with confidence intervals
from an analysis in which
the marker and pro-
gnostic variables are
included
10
18. If done, report results of
further investigations, such
as checking assumptions,
sensitivity analyses and
internal validation
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
19. Interpret the results in
the context of prespeci-
fied hypotheses and
other relevant studies;
include a discussion
of limitations of the study
5
20. Discuss implications for
future research and
clinical value
15
Score 12.5 14.5 15.5 15.5 12.0 10.0 11.5 9.0* 11.0 11.0 12.0 14.5 13.0 13.0 10.0* 14.0 12.5 14.0
We indicated whether the REMARK guidelines did apply (green), did not apply (red) or did only partly apply (yellow) to the relevant study and subsequently a general score on how well the guidelines were followed was computed for
each study (1, 0.5 or 0; maximum value of 19 or 17*).
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2005) and in transplanted kidney rejection (Kerjaschki et al, 2006)
where LYVE-1
þ/CD68
þ cells were shown to be incorporated
into newly dividing lymphatic vessels. These findings indicate
the fascinating possibility that LYVE-1
þ macrophage-like
cells may represent bone marrow derived progenitors with the
capacity to differentiate towards lymphatic vessel endothelium
as well as regulators of VEGF-C induced lymphoproliferation
(vide infra).
Podoplanin
Podoplanin is a B38-kd surface glycoprotein that is expressed in
osteoblastic cells, lung alveolar type I cells and kidney podocytes
(Wetterwald et al, 1996; Breiteneder-Geleff et al, 1997). The
specificity of podoplanin expression on lymphatic but not blood
vascular endothelium has been demonstrated in the skin
(Breiteneder-Geleff et al, 1999). However, podoplanin appears to
be only present in small lymphatic vessels and not in larger ones
that have smooth-muscle cells (Stacker et al, 2002). So far, there
is no evidence of podoplanin expression in BVECs (Stacker et al,
2002), suggesting that it can be considered as a reliable marker of
the lymphatic endothelium. Recently, it was indicated by Schacht
et al (2005) that the commercially available monoclonal D2–40
antibody specifically recognises human podoplanin. The antibody
has been shown to be a highly selective marker of lymphatic
endothelium in sections of both frozen and formalin-fixed
paraffin-embedded normal and neoplastic tissues (Kahn et al,
2002a) and has been proven valuable in detecting lymphatic
invasion in various malignant neoplasms (Kahn and Marks,
2002b). In a direct comparison of the D2–40 antibody and an
antibody against podoplanin on paraffin sections of a series of
head and neck squamous cell carcinomas, both antibodies were
shown to have extremely high specificity (99.7 and 98.8% for
podoplanin and D2–40) and sensitivity (92.6 and 97.3% for
podoplanin and D2–40) for lymphatic endothelium (Evangelou
et al, 2005).
A comparative study of antibodies directed at LYVE-1,
podoplanin, Prox-1 and the D2–40 antibody on serial sections
of breast carcinomas indicated that significantly more intra-
tumourous lymphatic vessels stained with D2–40 (Van der Auwera
et al, 2005), thus demonstrating that this marker is highly
sensitive for lymphatic endothelium. Besides being reactive with
lymphatic vessels, D2–40-staining has also been observed in basal
epithelial cell layers of the epidermis (Niakosari et al, 2005) and of
human breast and prostate gland (Agarwal et al, 2005; Zeng et al,
2005).
Just as tumour vasculature has a markedly different phenotype
from normal vessels, so it is highly likely that tumour lymphatic
vessels will differ from normal and gene array studies on lymphatic
endothelium isolated from tumours will be of major interest to
help develop new markers relevant to tumour therapy and
outcome. Fiedler et al (2006) very recently reported that the
CD34 protein, a recognised vascular endothelial marker, is
selectively expressed in tumour-associated LECs and not in resting
organ LECs. The expression of CD34 by tumour-associated LECs
was identified in colon cancer, breast cancer, lung cancer and
melanoma. These findings underline the importance of CD34 as an
activation antigen of human LECs and as a potential diagnostic
and prognostic tumour marker.
METHODOLOGY OF LYMPHANGIOGENESIS
QUANTIFICATION IN SOLID TUMOURS BY
HISTOMORPHOMETRY
Lymphatic vessel density
By analogy with angiogenesis, tumour-associated LVD is most
frequently assessed by counting the number of immunostained
vessels in tumour sections, as defined by Weidner et al (1991) in
1991. Microvessel density (MVD) is determined in vascular ‘hot
spots’ or areas giving the impression at low magnification of
containing numerous microvessels. Vascular ‘hot spots’ are
thought to represent localised areas of biological importance since
they originate from tumour cell clones with the highest angiogenic
potential which will predominantly enter the circulation and give
rise to vascularised metastases. Localised changes in oxygen
tension are indeed a strong angiogenic drive. The reproducibility
of the assignment of these ‘hot spots’ is a critical variable in the
analysis of MVD and the success of finding the relevant ‘hot spot’
depends on the training and experience of the investigator
(Vermeulen et al, 2002). The methodology of counting the number
of microvessel entities in regions with an elevated vascular density
has been adapted for the assessment of LVD, although this is based
on the assumption that a functional increase in lymphatic vessels
occurs in ‘hot spots’. Since data on the association of lymph-
angiogenesis with hypoxia are still contradictory, the relevance of
counting lymphatic vessels in ‘hot spots’, as opposed to an overall
lymphatic vessel count, has been questioned (Shields et al, 2004).
The number of lymphatic vessels in a microscopic field is the net
result of previous phases of tumour lymphangiogenesis and of
lymphatic vessel remodelling or regression, which implicates that
the measurement of LVD is not necessarily a reflection of the
ongoing tumour lymphangiogenesis. Nevertheless, several studies
LYVE-1
Desmoplakin
Podoplanin VEGFR-3
Prox-1 -Chemokine receptor D6
Figure 2 Representation of lymphangiogenic markers on lymphatic endothelial cells.
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lymphangiogenic factor expression, and with the occurrence of
lymphatic metastases and survival, suggesting that LVD contains
important information on the degree of tumour lymphatic
vasculature.
There is still a considerable debate about the role of
intratumourous vs peritumourous lymphatic vessels in the
pathology of primary human tumours. Several studies have
shown that the density of lymphatic vessels located immediately
adjacent to the tumour is associated with the presence of LN
metastases (Dadras et al, 2003; Bono et al, 2004; Franchi et al, 2004;
Gombos et al, 2005; Hachisuka et al, 2005; Kyzas et al, 2005;
Mou et al, 2005; Renyi-Vamos et al, 2005; Zeng et al, 2005; Massi
et al, 2006; Roma et al, 2006). Moreover, in a retrospective
prognostic study, Dadras et al (2003) found that the size of
peritumourous lymphatic vessels was the most significant
independent factor that correlates with LN metastasis in human
malignant melanomas. However, other studies show that intra-
tumourous and not peritumourous lymphatic vessels are vital for
lymphatic metastasis (Beasley et al, 2002; Hall et al, 2003; Maula
et al, 2003; Audet et al, 2005; Kuroyama et al, 2005; Kyzas et al,
2005; Massi et al, 2006).
The infiltration of lymphatic vessels into the tumour may have
a passive role in cancer metastasis by creating an increased
opportunity for metastatic tumour cells to leave the primary
tumour site but might also establish a paracrine signalling pathway
for tumour cell growth and invasion through the release of specific
growth factors or chemokines (Cassella and Skobe, 2002). Michaela
Skobe et al have shown that lymphatic capillaries activated by
factors produced by tumours, such as VEGF-C, promote tumour
cell invasion by increasing tumour cell transendothelial migration
through the expression of the CC-type chemokine ligand 1 on
LECs and its receptor CC-type chemokine receptor 8 on tumour
cells (Alitalo et al, 2004). Moreover, secondary lymphoid
chemokine is constitutively produced by LECs in the skin (Saeki
et al, 1999) and other organs (Gunn et al, 1998) and was found to
attract dendritic cells to the lymphatic vessels by interaction with
its primary receptor CCR7. This chemokine receptor is highly
expressed in human breast cancer cells, malignant breast tumours
and metastases, triggering actin polymerisation, pseudopodia
formation, and the directional migration and invasion of these
cells (Muller et al, 2001).
Chalkley counting
Although tumour-associated lymphangiogenesis has mainly been
assessed by counting the number of immunostained lymphatic
vessels, other techniques, such as Chalkley point overlap
morphometry, are available. This method involves the use of an
eyepiece graticule containing 25 randomly positioned dots, which
is rotated so that the maximum number of points is on or within
the vessels of the vascular ‘hot spot’. Thus, instead of counting the
individual microvessel, the overlaying dots are counted. Hall et al
(2003) investigated the relationship between LVD, determined by
Chalkley counting, and clinical and pathological variables in
patients with well-differentiated papillary thyroid carcinoma. In
a multivariate analysis, the Chalkley score was found to be
significantly associated with the presence of nodal metastases at
presentation. A similar association has also been shown in head
and neck cancer (Audet et al, 2005).
The Chalkley count is a reflection of the relative area taken
by the lymphatic vasculature and offers a suitable alternative
for LVD assessment according to Weidner’s guidelines. As no
decisions have to be made on whether adjacent stained structures
are separate microvessel or not, Chalkley point counting should
be a more objective approach. The most observer-dependent
step though still remains, that is, the selection of the vascular ‘hot
spot’.
Lymphatic endothelial cell proliferation (LECP)
LECP is measured by a double immunostaining of tumour sections
with antibodies directed at a LEC marker (antipodoplanin or anti-
LYVE-1) and a marker of proliferating cells (anti-Ki67 or anti-
PCNA). Lymphatic vessels containing proliferating nuclei have
been observed in breast cancer (Van der Auwera et al, 2005),
endometrial cancer (Koukourakis et al, 2005), head and neck
cancer (Beasley et al, 2002) and melanoma (Dadras et al, 2003;
Straume et al, 2003). This suggests the presence of active
intratumourous lymphangiogenesis, at least in some tumour types.
In addition to the sprouting of lymphatic vessels, the enlargement
of lymphatic vessels is also accompanied by the proliferation of
LECs. It has been reported that both lymphangiogenesis and
lymphatic hyperplasia play a role in tumour dissemination (Skobe
et al, 2001; Stacker et al, 2001; He et al, 2005). In a VEGF-C
overexpressing animal model, a tumour-induced increase in the
diameter of collecting lymphatic vessels was associated with an
enhanced passage of clusters of tumour cells to the sentinel LNs
(He et al, 2005). Increased lymphatic vessel perimeters and areas
were also found to be correlated with the occurrence of lymphatic
metastasis in some human tumours (Nathanson et al, 1997; Dadras
et al, 2003; Franchi et al, 2004; Van der Auwera et al, 2005; Liang
et al, 2006; Massi et al, 2006).
Computerised image analysis systems
The major drawbacks of the visual MVD counting method are its
inherent subjectivity and the difficulty of standardisation between
laboratories. In contrast, image cytometry is more objective and
reproducible and moreover, many image cytometry software
packages allow additional information on vessel luminal area
and vessel luminal perimeter. However, the widespread application
of image cytometry is hampered by the need for specialised
equipment to perform the analyses. Another limitation of this
method is the possibility of confounding signals of nonendothelial
structures in the stromal compartment. Choi et al (2005)
performed a direct comparison of visual and image cytometric
lymphatic vessel density counting on D2–40-immunostained
sections of invasive breast carcinomas. They used an automated
scanning microscope and an automated image analysis application
that identified stained ring-like structures based on colour and
morphometry in areas marked during direct microscopic micro-
vessel counting. D2–40 microvessel densities determined by direct
microscopy and image cytometry were significantly correlated.
However, only the visual D2–40 data were associated with LN
status and VEGF-family gene expression.
SURROGATE MARKERS OF TUMOUR-ASSOCIATED
LYMPHANGIOGENESIS
Histopathological markers
Fibrotic focus Similar to angiogenesis, the fibrotic focus and the
growth pattern might be considered as surrogate histopathological
markers for tumour-associated lymphangiogenesis (Vermeulen
et al, 2002). A fibrotic focus is defined as a fibrosclerotic scar-like
area replacing necrosis in the centre of a carcinoma. The presence
of a fibrotic focus in breast cancer is considered to be a surrogate
marker of hypoxia-driven angiogenesis as it was shown to predict
for higher MVD and for a higher fraction of proliferating
endothelial cells (Jitsuiki et al, 1999; Colpaert et al, 2003a).
Similarly, its presence in breast cancer is associated with a higher
LECP but not with a higher LVD (Van der Auwera et al, 2005).
Tumour growth pattern It has been previously shown that
different growth patterns in primary breast cancer reflect
differences in angiogenesis. In the infiltrative growth pattern, the
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a significant disturbance of the tissue architecture. Expansively
growing breast tumours form a well-circumscribed nodule
consisting of carcinoma cells and desmoplastic connective tissue.
The endothelial cell proliferation fraction and the Chalkley count
were highest in the expansive growth pattern (Colpaert et al,
2003b; Van den Eynden et al, 2005). Recently, it became clear that
the growth pattern is also a histological surrogate marker of
lymphangiogenesis (Van der Auwera et al, 2005). LECP, both in
the tumour parenchyma and at the tumour periphery, was
significantly higher in the expansive growth pattern compared
with the infiltrative growth pattern. In addition, the intratumour-
ous LVD was highest in the infiltrative growth pattern. An
association between the growth pattern and the presence of
lymphangiogenesis has also been observed in human non-small-
cell lung cancer (Renyi-Vamos et al, 2005).
Tumour levels of lymphangiogenic growth factors The expression,
in various human cancers, of lymphangiogenic factors such as
VEGF-C and VEGF-D, is closely related to tumour-induced
lymphatic dilatation or lymphangiogenesis (less frequent) and
thereby to LN metastasis (Pepper et al, 2003a).
In breast cancer, increased expressions of VEGF-C and VEGF-D
in the tumour cells, both on the mRNA and protein level, are
known to be associated with high LVD, lymphatic invasion and LN
metastasis (Nakamura et al, 2003; Choi et al, 2005; Nakamura et al,
2005; Huang et al, 2006; Li et al, 2006). Straume et al (2003) have
compared LVD, evaluated by counting the number of LYVE-1-
positive vessels in hot spots, with the protein expression of several
(lymph)angiogenic growth factors in cutaneous melanoma speci-
mens. Among the factors tested (VEGF-A, VEGF-C, VEGFR-1,
VEGFR-2, VEGFR-3, FGF-2, ephrin-A1/2, interleukin-8 and
thrombospondin-1), only the expression of FGF-2 was significantly
associated with increased LVD. Furthermore, evidence for the
existence of an association between VEGF-C or VEGF-D expres-
sions and the number of tumour lymphatic vessels has also been
provided for colorectal cancer (Ohno et al, 2003; Jia et al, 2004;
Wang et al, 2005), gastric cancer (Yonemura et al, 2001; Onogawa
et al, 2005; Shida et al, 2005; Juttner et al, 2006), thyroid cancer
(Yasuoka et al, 2005), early-stage squamous cell cancer of the
urerine cervix (Gombos et al, 2005) and pancreatic cancer (Sipos
et al, 2004). In non-small-cell lung cancer, however, the existence
of an association between VEGF-C expression and LVD remains
contradictory (Lu et al, 2005; Renyi-Vamos et al, 2005; Takanami,
2006).
Other markers
The main disadvantage of the histological surrogate markers of
lymphangiogenesis is the inherent interobserver variability. A
more objective approach is the quantification of circulating levels
of lymphangiogenic growth factors, such as VEGF-C and VEGF-D,
and of circulating lymphatic endothelial progenitor cells.
Circulating levels of lymphangiogenic growth factors From a
practical point of view, the detection of circulating levels of VEGF-
C and VEGF-D protein/antigen in preoperative blood samples
might be a useful indicator of advanced disease.
In some cancers, circulating lymphangiogenic factors are
increased compared to healthy individuals or patients with benign
tumours, for example, VEGF-C in lung non-small-cell carcinoma
(Tamura and Ohta, 2003). However, in ovarian carcinoma, breast
carcinoma, cervix adenocarcinoma and head and neck carcinoma
this seems not to be the case (Table 3). Furthermore, in colorectal
cancer, VEGF-C is increased in cancer patients but not VEGF-D
(George et al, 2001; Duff et al, 2005). In lung non-small-cell
carcinoma, cervical squamous cell carcinoma and colorectal
cancer, a higher preoperative circulating VEGF-C level strongly
correlated with LN metastasis and also lymphatic vessel invasion
(the latter only in lung non-small-cell carcinoma). Concerning
VEGF-D, plasma levels are increased in patients with angio-
sarcoma compared to healthy controls, and in one study on
prostate carcinoma, a correlation between VEGF-D levels and LN
metastasis was found (Kaushal et al, 2005).
The above results should be seen in context, since there are only
a few studies on circulating VEGF-C and VEGF-D levels compared
to the expression of their mRNA or protein levels in cancer.
Lymphatic endothelial progenitor cells (LEPCs) Bone marrow-
derived circulating endothelial precursor cells contribute to newly
blood vessel formation both under physiological and pathological
conditions. The measurement of circulating endothelial cells in
peripheral blood of patients with cancer has been integrated in
clinical studies exploring the efficacy of antiangiogenic therapies.
Evidence for the existence of LEPCs has only recently been found.
Salven et al (2003) identified a subset of CD34þ cells that
coexpress the stem/precursor cell marker CD133 and VEGFR-3.
These cells are functionally nonadherent endothelial precursor
cells that can differentiate into mature adherent VEGFR-3þ
endothelial cells in the presence of vascular growth factors. In a
corneal lymphangiogenesis model of irradiated mice reconstituted
with donor BM cells, both CD34þ/VEGFR-2þ cells and CD34þ/
Table 3 Studies on circulating VEGF-C and VEGF-D levels in patients with cancer
Tumour Markers (source) Comments Reference
Colorectal ca. VEGF-C (plasma) Increased in cancer patient compared to control Duff et al (2003)
Significantly higher in advanced Dukes C and D (LN+) compared to Dukes A and B (LN )
VEGF-C (plasma) Decreased expression in cancer patient compare to control Duff et al (2005)
VEGF-D (serum) No difference between cancer and control George et al (2001)
VEGF-D (plasma) No difference between cancer and control Duff et al (2005)
Non-small cell lung ca. VEGF-C (serum) Increased in carcinoma compared to benign lesions and control individuals Tamura and Ohta (2003)
Correlation with pathologic stage, LN metastasis and lymphatic vessel invasion
VEGF-C (serum) Correlation with pathologic stage, LN metastasis and lymphatic vessel invasion Tamura et al (2004a,b)
Cervical ca. VEGF-C (serum) Increased in squamous cervical cancer compared to controls Mitsuhashi et al (2005)
Correlation with FIGO stage, tumour size and recurrence but not with LN metastasis
No increase in cervical adenocarcinoma compared to controls
VEGF-C (serum) Increased in cervical cancer compared to controls Mathur et al (2005)
Prostate ca. VEGF-D (plasma) Increased in early stage (LN neg) compare to late stage (LN or bone) metastasis Kaushal et al (2005)
Angiosarcoma VEGF-D (serum) Increased compared to controls Amo et al (2004)
Ovarian ca. VEGF-C (serum) Not increased compared to controls Mathur et al (2005)
Breast ca. VEGF-D (plasma) Not increased compared to controls Hoar et al (2004)
Head and neck ca. VEGF-C (plasma) Not increased compared to controls Strauss et al (2005)
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formed lymphatic vessels (Religa et al, 2005). A second population
of candidate LECPs has now been identified. A subpopulation of
human circulating CD14þ monocytes was shown to also express
VEGFR-3 on its surface and could be stimulated in vitro to express
VEGF-C as well as the LEC marker podoplanin (Schoppmann et al,
2002; Kerjaschki et al, 2006). It was speculated that these cells
participate in inflammation-associated de novo lymphangio-
genesis in nephrectomy specimens of rejected kidney transplants
(Kerjaschki et al,2 0 0 6 ) .M a r u y a m aet al (2005) have provided direct
evidence of the incorporation of transdifferentiated monocytes-
macrophages into growing lymphatic vessels. In a mouse corneal
transplantation model, macrophages could transdifferentiate into
LECs by forming cell aggregates and vesicles that integrate into an
existing lymphatic vessel. Moreover, in vitro experiments demon-
strated that CD11bþ macrophages were capable of forming tube-
like structures that expressed markers of lymphatic endothelium
such as LYVE-1 and podoplanin. These data indicate a novel role
for macrophages in lymphangiogenesis. Gene expression profiling
studies are necessary for characterisation of LECPs in peripheral
blood and will improve our understanding of lymphatic endo-
thelial function in cancer.
RECOMMENDED METHODOLOGY
So far, studies on the importance of lymphangiogenesis for tumour
growth have yielded inconsistent conclusions and this is mostly
due to differences in the applied methodology and the lack of
standardisation. In Table 4, a proposition for the standardisation
of the immunohistochemical method for lymphangiogenesis
assessment is given.
Methods of lymphangiogenesis quantification in solid tumours
rely upon the use of markers that allow an accurate discrimination
between lymphatic vessels and blood vessels in histological tissue
sections. At present the most reliable marker is likely to be
podoplanin, which is recognised by the monoclonal D2–40
antibody with a high specificity and sensitivity. Although LYVE-
1 has been proven valuable for distinguishing between lymphatic
vessels and blood vessels in histological tissue sections, it has been
reported that LYVE-1 expression in tumour lymphatic vessels can
be downmodulated, for example, in breast cancer (Stessels et al,
2004; Van der Auwera et al, 2004). None of the proposed markers
fulfils the criteria of an ideal lymphatic vessel marker, which
should be exclusively found on all types of LECs in all pathological
conditions. Therefore, the use of multiple immunohistochemical
stains on serial sections of random subgroups of cases is
recommended to confirm the actual staining of lymphatic vessels.
The best combination of markers of the lymphatic endothelium
could vary on the tissue type. As more insights on the molecular
pathways of lymphatic differentiation emerge, novel potential
markers of the lymphatic endothelium might be identified.
The quantification of LVD has been proven valuable for the risk
assessment of regional LN involvement in patients with cancer. By
using the Chalkley point overlap morphometric technique the
observer-dependent step of measuring LVD can be abolished since
the Chalkley count is a relative area estimate rather than a true
vessel count. However, the method that most likely reflects the
ongoing tumour lymphangiogenesis would be the analysis of
proliferating LECs, which can be assessed by a double immuno-
stain with podoplanin to stain lymphatic vessels, together with
Ki-67 to stain proliferating cells.
As it seems that the patterns of lymphangiogenesis vary among
malignancies lymphangiogenesis should be evaluated both in-
tratumourous and at the tumour periphery.
SUMMARY AND FUTURE DIRECTIONS
For every major type of cancer LN involvement is strongly
associated with poor survival and usually is one of the major
factors associated with poor prognosis. Whether this is the
mechanism for poor prognosis or a marker for aggressive
underlying molecular pathway is difficult to determine clinically.
The pathway of metastasis via lymphatic vessels, regional LNs and
then into the systemic circulation is an accepted pathway of
metastasis, although in recent years the emphasis has switched to
the importance of angiogenesis and direct systemic spread.
Nevertheless, it is not possible to quantify the relative contribution
to spread currently between these different routes and the very
strong association of LN involvement with outcome is a key factor
in the staging of all cancers. Understanding such an important
prognostic factor, the mechanisms regulating it and how it might
be related to prognosis are important issues regardless of any
possible therapeutic approach.
Understanding the mechanisms by which lymphangiogenesis
occurs or tumour cells migrate to lymphatic vessels, or indeed
understanding how new lymphatic vessels are generated from
other cell types such as macrophages or circulating progenitor cells
is all highly relevant to potential mechanisms of growth of
metastases. VEGF-A-overexpressing primary tumours have been
shown to induce sentinel LN lymphangiogenesis before meta-
stasising (Hirakawa et al, 2005) and also in human cancer
lymphangiogenesis appears to occur in secondary sites, for
example, in LN metastases of breast cancer (Van den Eynden
et al, 2006). This might suggest that primary tumours begin
preparing their future metastatic site by inducing the growth of
new lymphatic vessels.
Table 4 Proposed standard method for the assessment of lymphangiogenesis
Methodological
aspect Proposed standard Advantage
1. Immunostaining Double immunostain with the D2-40 monoclonal antibody and the anti-Ki-67 monoclonal antibody Highly specific and sensitive
marker of the lymphatic
endothelium
2. Selection of the
quantification
fields
Manual vascular hot spot selection at low magnification (e.g.  10) – in viable tumour tissue and adjacent
(e.g. within diameter of one field at  200 magnification) stromal tissue
All highly vascular areas can
be detected
3. Quantification of
lymphatic vessels
Chalkley point graticule method Exclusion of the subjective
step of identifying individual
lymphatic vessels in an
endothelial cell cluster
4. Quantification of
LEC proliferation
Counting of the number of proliferating LECs vs nonproliferating LECs Reflection of the ongoing
lymphangiogenesis
5. Number of
observers
Sequential assessment by two investigators More practical in a clinical
setting than co-observation
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multiple factors that are produced by various cell types. Some of
the originally angiogenic signalling molecules, such as VEGF-A
and FGF-2, have been implicated in the control of lymphatic vessel
growth as well, indicating a close link between angiogenesis and
lymphangiogenesis. Novel insights into the interrelationship
between both processes will lead to a better understanding of the
mechanisms of growth of metastases and will have important
implications for cancer therapy. Many potent antiangiogenic
compounds that can be used in anticancer therapy have been
identified and are currently being investigated in clinical trials. It is
not clear whether these antiangiogenic agents also affect lymph-
angiogenesis and hence, biopsy studies should also stain for effects
on lymphatic vessels to dissect their possible role in response to
therapy.
The search for specific lymphangiogenesis inhibitors has led to
the identification of a number of potential antilymphangiogenic
compounds that have been shown to suppress metastasis of
tumours to regional LNs in experimental animal models. These
include antibodies that either block the activity of the ligands
VEGF-C and VEGF-D directly by binding to the ligand or by
preventing the interaction with VEGFR-3 and soluble dimeric
fusion proteins containing the extracellular ligand binding site of
VEGFR-3 (Banerji et al, 1999; Thiele and Sleeman, 2006). However,
many questions concerning their potential therapeutic role in the
management of human cancer are raised. Although the point could
be made that when patients first present they already have
lymphatic metastasis or not, and these will be treated surgically
or with other means, it would be highly desirable to prevent
metastasis in patients who are at increased risk of second
primaries. A clear example is breast cancer with second cancers
either in the treated breast or the opposite breast and reducing the
incidence of new primaries, but also reducing the instance of
secondary deposits from the new primaries is a key therapeutic
aim.
Understanding the mechanisms of lymphangiogenesis
could be helpful in the adjuvant situation of managing common
cancers with treatment aimed at both stopping proliferation
and recurrence of primary tumours and their regional
metastases.
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